Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-04-2008 | ORIGINAL PAPER

Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey

Authors: Jaana Suvisaari, MD, PhD, Jonna Perälä, MD, Samuli I. Saarni, MD, MSocSc, Tommi Härkänen, PhD, Sami Pirkola, MD, PhD, Matti Joukamaa, MD, PhD, Seppo Koskinen, MD, PhD, MSc, Jouko Lönnqvist, MD, PhD, Antti Reunanen, MD, PhD

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 3/2008

Abstract

Schizophrenia and other psychotic disorders are associated with increased risk of developing type 2 diabetes. However, previous studies are mainly based on clinical samples where the comorbidity may be stronger. We investigated in a general population survey the prevalence of type 2 diabetes in persons with psychotic disorders and in users of antipsychotic medication. The study was based on a nationally representative two-stage cluster sample of 8,028 persons aged 30 or over from Finland. Diagnostic assessment of psychotic disorders combined SCID-I interview and case note data. Prevalences of type 2 diabetes, adjusting for age and sex, were estimated by calculating predicted marginals. The prevalence estimate of type 2 diabetes was 22.0% among subjects with schizophrenia, 13.4% among subjects with other nonaffective psychosis and 6.1% in subjects without psychotic disorders. Only two subjects (3.4%) with affective psychosis had type 2 diabetes. Users of all types of antipsychotic medication had increased prevalence of type 2 diabetes. Our results suggest that type 2 diabetes is a major health concern among persons with schizophrenia and other nonaffective psychotic disorders and also in users of antipsychotic medication, but persons with affective psychosis in the general population may not have increased prevalence of type 2 diabetes.

Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686–1696PubMed

Aromaa A, Koskinen S (eds) (2004) Health and functional capacity in Finland. Baseline Results of the Health 2000 Health Examination Survey. Publications of the National Public Health Institute, B12. Available at http://www.ktl.fi/terveys2000/index.uk.html (accessed May 25, 2007)

Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335–1342PubMed

Bellivier F (2005) Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry 20:S335–S339PubMedCrossRef

Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697–701PubMedCrossRef

Cassidy F, Ahearn E, Carroll BJ (1999) Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 156:1417–1420PubMed

Cohen D, Grobbee DE, Stolk RP, Gispen-De-Wied CC (2006) Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorder. Diabetes Care 29:786–791PubMedCrossRef

Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753–760PubMed

De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2:14PubMedCrossRef

10.

De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87–93PubMedCrossRef

11.

Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903–912PubMed

12.

Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (2001) Executive summary of The Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef

13.

Gianfrancesco F, Grogg A, Mahmoud R, Wang R-H, Meletiche D (2003) Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. Clin Ther 25:1150–1171PubMedCrossRef

14.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D’Agostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53PubMedCrossRef

15.

Gough SC, O’Donovan MC (2005) Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 19(6 Suppl):47–55PubMedCrossRef

16.

Heistaro S (ed) (2005) Menetelmäraportti. Terveys 2000 -tutkimuksen toteutus, aineisto ja menetelmät (Implementation, data and methods of the Health 2000 Survey, in Finnish). Publications of the National Public Health Institute, B6

17.

Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 157:975–981PubMedCrossRef

18.

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC (2005) Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents. Arch Gen Psychiatry 62:19–28PubMedCrossRef

19.

Hung C-F, Wu C-K, Lin P-Y (2005) Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuro-Psychopharmacol Biol Psychiatry 29:523–527CrossRef

20.

Jin H, Meyer JM, Jeste DV (2004) Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 71:195–212PubMedCrossRef

21.

Kilbourne AM, Cornelius JR, Han X, Haas GL, Salloum I, Conigliaro J, Pincus HA (2005) General-medical conditions in older patients with serious mental illness. Am J Geriatr Psychiatry 13:250–254PubMedCrossRef

22.

Koponen H, Saari K, Savolainen M, Isohanni M (2002) Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication. Eur Arch Psychiatry Clin Neurosci 252:294–298PubMedCrossRef

23.

Kuehn BM (2005) FDA warns antipsychotic drugs may be risky for elderly. JAMA 293:2462PubMedCrossRef

24.

Kupfer DJ (2005) The increasing medical burden in bipolar disorder. JAMA 293:2528–2530PubMedCrossRef

25.

Lamberti JS, Crilly JF, Maharaj K, Olson D, Wiener K, Dvorin S, Costea GO, Bushey MP, Dietz MB (2004) Prevalence of diabetes mellitus among outpatients with severe mental disorders receiving atypical antipsychotic drugs. J Clin Psychiatry 65:702–706PubMedCrossRef

26.

Lazarus R, Sparrow D, Weiss ST (1997) Handgrip strength and insulin levels: cross-sectional and prospective associations in the Normative Aging Study. Metabolism 46:1266–1269PubMedCrossRef

27.

Lee J (1981) Covariance adjustment of rates based on the multiple logistic regression model. J Chronic Dis 34:415–426PubMedCrossRef

28.

Leslie DL, Rosenheck RA (2004) Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 161:1709–1711PubMedCrossRef

29.

Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160:290–296PubMedCrossRef

30.

Montonen J, Knekt P, Harkanen T, Jarvinen R, Heliovaara M, Aromaa A, Reunanen A (2005) Dietary patterns and the incidence of type 2 diabetes. Am J Epidemiol 161:219–227PubMedCrossRef

31.

Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio P (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68–73PubMedCrossRef

32.

Nasrallah H, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 86:15–22PubMedCrossRef

33.

National Agency for Medicines and Social Insurance Institution (2005) Finnish Statistics on Medicines 2004. Edita Prima Oy, Helsinki

34.

National Agency for Medicines and Social Insurance Institution (2001) Finnish Statistics on Medicines 2000. Edita Oy, Helsinki

35.

Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G (2002) Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337–345PubMedCrossRef

36.

Patja K, Jousilahti P, Hu G, Valle T, Qiao Q, Tuomilehto J (2005) Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. J Intern Med 258:356–362PubMedCrossRef

37.

Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, Partonen T, Tuulio-Henriksson A, Hintikka J, Kieseppä T, Härkänen T, Koskinen S, Lönnqvist J (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64:19–28PubMedCrossRef

38.

Philippe A, Vaiva G, Casadebaig F (2005) Data on diabetes from the French cohort study in schizophrenia. Eur Psychiatry 20:S340–S344PubMedCrossRef

39.

Pierce M, Keen H, Bradley C (1995) Risk of diabetes in offspring of parents with non-insulin-dependent diabetes. Diabet Med 12:6–13PubMedCrossRef

40.

Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV (2002) Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 70:19–26PubMedCrossRef

41.

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care 20:1183–1197

42.

Research Triangle Institute (2004) SUDAAN Language Manual, Release 9.0. Research Triangle Park, NC: Research Triangle Institute

43.

Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289PubMedCrossRef

44.

Stewart R, Liolitsa D (1999) Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 16:93–112PubMedCrossRef

45.

Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346PubMedCrossRef

46.

Subramaniam M, Chong S-A, Pek E (2003) Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 48:345–347PubMed

47.

Susce MT, Villanueva N, Diaz FJ, de Leon J (2005) Obesity and associated complication in patients with severe mental illnesses: a cross-sectional survey. J Clin Psychiatry 66:167–173PubMed

48.

van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods. J Clin Psychiatry 67:1493–1500PubMedCrossRef

49.

Weiss AP, Henderson DC, Weiburg JB, Goff DC, Meigs JB, Cagliero E, Grant RW (2006) Treatment of cardiac risk factors among patients with schizophrenia and diabetes. Psychiatr Serv 57:1145–1152PubMedCrossRef

50.

World Health Organization Expert Committee (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation, part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization

Title: Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey
Authors: Jaana Suvisaari, MD, PhD
Jonna Perälä, MD
Samuli I. Saarni, MD, MSocSc
Tommi Härkänen, PhD
Sami Pirkola, MD, PhD
Matti Joukamaa, MD, PhD
Seppo Koskinen, MD, PhD, MSc
Jouko Lönnqvist, MD, PhD
Antti Reunanen, MD, PhD
Publication date: 01-04-2008
Publisher: D. Steinkopff-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 3/2008
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-007-0762-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life

Depressive symptomatology correlates with phantom breast syndrome in mastectomized women

EEG-vigilance differences between patients with borderline personality disorder, patients with obsessive-compulsive disorder and healthy controls

Changes in regional cerebral blood flow demonstrated by 99mTc-HMPAO SPECT in euthymic bipolar patients

Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder

Erratum